PUBLICATION
In vivo drug discovery for increasing incretin-expressing cells identifies DYRK inhibitors that reinforce the enteroendocrine system
- Authors
- Chu, L., Terasaki, M., Mattsson, C.L., Teinturier, R., Charbord, J., Dirice, E., Liu, K.C., Miskelly, M.G., Zhou, Q., Wierup, N., Kulkarni, R.N., Andersson, O.
- ID
- ZDB-PUB-220824-34
- Date
- 2022
- Source
- Cell chemical biology 29(9): 1368-1380.e5 (Journal)
- Registered Authors
- Andersson, Olov, Liu, Ka-Cheuk
- Keywords
- DYRK, GIP, GLP-1, chemical screen, diabetes, enteroendocrine cells, incretin hormones, mouse, zebrafish
- MeSH Terms
-
- Animals
- Diabetes Mellitus, Experimental*
- Diabetes Mellitus, Type 2*
- Drug Discovery
- Gastric Inhibitory Polypeptide/metabolism
- Gastric Inhibitory Polypeptide/therapeutic use
- Glucagon-Like Peptide 1/genetics
- Glucagon-Like Peptide 1/metabolism
- Glucagon-Like Peptide 1/therapeutic use
- Glucose/metabolism
- Incretins/metabolism
- Incretins/therapeutic use
- Mice
- Tyrosine
- Zebrafish/metabolism
- PubMed
- 35998625 Full text @ Cell Chem Biol
Citation
Chu, L., Terasaki, M., Mattsson, C.L., Teinturier, R., Charbord, J., Dirice, E., Liu, K.C., Miskelly, M.G., Zhou, Q., Wierup, N., Kulkarni, R.N., Andersson, O. (2022) In vivo drug discovery for increasing incretin-expressing cells identifies DYRK inhibitors that reinforce the enteroendocrine system. Cell chemical biology. 29(9):1368-1380.e5.
Abstract
Analogs of the incretin hormones Gip and Glp-1 are used to treat type 2 diabetes and obesity. Findings in experimental models suggest that manipulating several hormones simultaneously may be more effective. To identify small molecules that increase the number of incretin-expressing cells, we established a high-throughput in vivo chemical screen by using the gip promoter to drive the expression of luciferase in zebrafish. All hits increased the numbers of neurogenin 3-expressing enteroendocrine progenitors, Gip-expressing K-cells, and Glp-1-expressing L-cells. One of the hits, a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor, additionally decreased glucose levels in both larval and juvenile fish. Knock-down experiments indicated that nfatc4, a downstream mediator of DYRKs, regulates incretin+ cell number in zebrafish, and that Dyrk1b regulates Glp-1 expression in an enteroendocrine cell line. DYRK inhibition also increased the number of incretin-expressing cells in diabetic mice, suggesting a conserved reinforcement of the enteroendocrine system, with possible implications for diabetes.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping